Jakob Lindberg, Oncopeptides CEO
January 24, 2022 07:11 AM ESTUpdated January 25, 02:35 PM
FDA+
Marketing

Months af­ter pulling on­ly drug from US, On­copep­tides takes back with­draw­al re­quest — but stays mum on why

Amber Tong

What hap­pens when you pull a re­quest to pull your drug from the mar­ket?

On­copep­tides is try­ing to find out, re­veal­ing late Fri­day that it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

A service from the Financial Times